(010) Association between the Use of Glucagon-like Peptide 1 Agonist and the Risk of Psoriasis in Diabetes Patients Compare to Dipeptidyl Peptidase-4 inhibitors in Taiwan
Pharmacist Chang-Gung Memorial Hospital, Linkou Taoyuan City, Taiwan (Republic of China)
Background: Diabetes and psoriasis are prevalent diseases with chronic conditions, with innate immune system disorders. Dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) agonists are incretin-based therapies for patients with type 2 diabetes (T2D). Glucagon-like peptide 1 regulates invariant natural killer T (iNKT) cells t, while DPP-4 is a multifunctional, transmembrane glycoprotein that has a co-stimulatory function in the immune response. In recent years, the novel function of these agents have been discovered. Increasing studies are focusing on their potential role in inflammatory disorders.
Objectives: To identify the association between GLP-1 agonists use and the risks of developing psoriasis compared to DPP-4 inhibitors.
Methods: We performed a population-based, retrospective cohort study. Patients using GLP-1 agonists and DPP-4 inhibitors were identified from the Chang Gung Research Database (CGRD) between January 1, 2008, and December 31, 2020 and were followed to December 31, 2022. The main outcome was psoriasis diagnoses from CGRD. Propensity score matching was performed according to age, sex, index year, and Charlson Comorbidity Index using a ratio of 1:1. Incidence rates (IR), incidence rate ratios (IRR) and 95% confidence intervals (CI) were estimated using the Cox regression model.
Results: The final matched cohort of 6,134 patients was included in our study. The average follow-up time was 4.75±2.28 years. The IR of psoriasis in GLP-1 agonist patients and in DPP-4 patients were 7.56 (per 1,000 patient-year) and 6.31. The IRR of psoriasis was 1.82 (95% CI 1.23-2.71).
Conclusions: The final matched cohort of 6,134 patients was included in our study. The average follow-up time was 4.75±2.28 years. The IR of psoriasis in GLP-1 agonist patients and in DPP-4 patients were 7.56 (per 1,000 patient-year) and 6.31. The IRR of psoriasis was 1.82 (95% CI 1.23-2.71).